X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Novartis will accelerate the development of DTx-1252, a novel, potential first-in-class, FALCON siRNA candidate targeting PMP22, for the treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A).
Lead Product(s): DTx-1252
Therapeutic Area: Genetic Disease Product Name: DTx-1252
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $1,000.0 million Upfront Cash: $500.0 million
Deal Type: Acquisition July 17, 2023
Details:
DTx-1252 is a potential first-in-class FALCON™ siRNA therapeutic for treatment of CMT1A. By repressing PMP22, DTx-1252 reverses CMT1A in a mouse model that faithfully recapitulates the genetic and clinical manifestations of the disease.
Lead Product(s): DTx-1252
Therapeutic Area: Genetic Disease Product Name: DTx-1252
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2023
Details:
Proceeds from the financing will be used to advance DTx’s pipeline utilizing its novel FALCON (Fatty Acid Ligand Conjugated OligoNucleotide) platform technology.
Lead Product(s): RNA-based therapeutics
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 01, 2021
Details:
The award, along with prior and pending grants, will enable DTx to expand the application of its lipid conjugate technology for the delivery of oligonucleotides as potential treatment for neurodegenerative diseases.
Lead Product(s): siRNAs
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Alzheimer's Association
Deal Size: $0.4 million Upfront Cash: Undisclosed
Deal Type: Funding May 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
